A 2026 UK review of the acetylcholine mechanism, the ASCOMALVA Alzheimers trial and 2023 meta-analysis, the Ziegenfuss 2008 gym study, the reassuring 2025 dementia data and the unresolved stroke question versus Dihexas unproven HGF/c-Met synaptogenesis and the c-Met concern
Clinical studies most often report mild side effects, including nausea, vomiting, diarrhea, heartburn, gas, headache, and general digestive discomfort.27 A 2021 safety review of high-dose NAC in chronic respiratory diseases found that oral doses between 600mg and 3,000mg daily were generally well tolerated, with gastrointestinal symptoms reported but not consistently more often than placebo.35 That doesnt mean NAC is risk-free
What the Research Says About Microdose Tirzepatide Here is the honest state of published evidence on subtherapeutic tirzepatide as of 2026: SURMOUNT-1 (tirzepatide 5/10/15 mg, 72 weeks): mean body-weight loss of 15.0%, 19.5%, and 22.5% vs
That said, the goal isn't to keep you on medication forever your provider will talk with you about duration, tapering, and what an exit looks like